Dietary methionine restriction targets one carbon metabolism in humans and produces broad therapeutic responses in cancer

Xia Gao, Sydney M. Sanderson, Ziwei Dai, Michael A. Reid, Daniel E. Cooper, Min Lu, John P. Richie, Amy Ciccarella, Ana Calcagnotto, Peter G. Mikhael, Samantha J. Mentch, Juan Liu, Gene P. Ables, David G. Kirsch, David S. Hsu, Sailendra N. Nichenametla, Jason W. LocasalebioRxiv 2019 · DOI

TL;DR

This study reveals that restricting dietary methionine (MR) can significantly impact cancer metabolism, leading to therapeutic responses in various cancer models. This dietary intervention works by altering the "one-carbon metabolism" pathway, which is also a target of conventional cancer therapies like chemotherapy and radiation, suggesting a synergistic approach to cancer treatment.

What Problem Does This Paper Address?

While nutrition is known to influence health and disease, its precise role in cancer treatment, particularly how dietary interventions can specifically target cancer metabolism, remains largely unclear. Cancer cells often exhibit altered metabolic pathways to fuel their rapid growth. Conventional cancer therapies, such as chemotherapy and radiation, also frequently target these metabolic pathways. However, it's not well understood if dietary changes can complement or enhance these established treatments by influencing the same metabolic targets. This paper investigates whether a specific dietary intervention, methionine restriction (MR), can modulate cancer metabolism in a way that synergizes with existing cancer therapies.

Methods

The researchers employed a multi-pronged approach:

  • Metabolomics: This was a core technique, used extensively to profile the metabolic changes in plasma, tumors, and liver tissues from mice and in plasma from human subjects. They used comparative metabolomics and a technique called Singular Value Decomposition (SVD) to analyze dynamic metabolic changes over time.
  • Animal Models: They utilized several mouse models:
  • Healthy mice: To understand the systemic metabolic effects of MR.
  • Colorectal Cancer Patient-Derived Xenografts (PDX): These models mimic human tumors and were used to test MR's effect on chemoresistant cancers.
  • Autochthonous Soft Tissue Sarcoma Model: This genetically engineered mouse model allowed them to study MR's impact on radiation-resistant tumors.
  • Cell Culture Experiments: Primary cancer cells were used for "rescue" experiments to pinpoint which metabolic components were essential for MR's effects.
  • Human Dietary Study: A controlled feeding study with healthy human volunteers was conducted to assess if MR elicits similar metabolic changes in humans as observed in mice.
  • Statistical Analysis: Spearman correlation was used to compare metabolic profiles across different models and tissues. Multidimensional scaling (MDS) was employed to visualize these relationships.

Datasets

The study utilized metabolomics data generated from:

  • Plasma, tumor, and liver samples from mice subjected to control or methionine-restricted diets.
  • Plasma samples from healthy human volunteers undergoing a methionine-restricted diet.
  • Colorectal cancer patient-derived xenograft (PDX) models.
  • Autochthonous soft tissue sarcoma mouse models.

The metabolomics data reported in this study were deposited to Mendeley Data.

Key Insights and Ideas

  • Targeting a Shared Pathway: The most striking insight is that dietary methionine restriction (MR) directly impacts the "one-carbon metabolism" pathway, which is also a key target for many cancer therapies (chemotherapy, radiation). This suggests a powerful opportunity for synergistic treatment strategies.
  • Cell-Autonomous Effects: MR's anti-cancer effects are not solely systemic; they also involve direct, cell-autonomous disruptions to cancer cell metabolism, particularly affecting nucleotide synthesis and redox balance.
  • Conserved Metabolic Response: The metabolic alterations induced by MR, particularly in cysteine and methionine metabolism, are remarkably conserved across different mouse models and even in healthy humans, indicating a fundamental biological response.
  • Dietary MR as a Sensitizer: MR significantly enhances the efficacy of 5-fluorouracil (5-FU) chemotherapy and radiation therapy in preclinical models, suggesting it can overcome resistance mechanisms.
  • Broader Metabolic Impact: Beyond methionine, MR influences other critical metabolic pathways, including nucleotide and redox metabolism, which are vital for cell proliferation and survival.

Key Results

  • Tumor Growth Inhibition: MR alone inhibited tumor growth in chemoresistant RAS-driven colorectal cancer PDX models and radiation-resistant soft tissue sarcomas.
  • Synergy with Therapies: MR significantly enhanced the anti-tumor effects of 5-FU chemotherapy and radiation therapy in preclinical models. For instance, in sarcoma models, MR combined with radiation substantially reduced tumor growth and extended tumor tripling time by 52%.
  • Metabolic Alterations: MR consistently altered methionine and sulfur metabolism in tumors, plasma, and liver. It also disrupted nucleotide metabolism and cellular redox balance, which are crucial for cancer cell proliferation.
  • Human Translation: A controlled human feeding study showed that MR in healthy individuals resulted in similar systemic metabolic changes, particularly in cysteine and methionine metabolism, as observed in mice.

Limitations and Future Work

  • Tumor-Type Specificity: While MR shows broad effects, the paper notes that dietary MR globally affects metabolism in a "species- and tumor-type-dependent manner." Future work could explore this further.
  • Short-Term MR in Humans: The human study involved a 3-week MR diet. The authors suggest that "future studies assessing how short MR could result in such specific metabolic changes in humans are warranted."
  • Mechanistic Details: While the study identifies key metabolic disruptions (nucleotide synthesis, redox balance), further detailed mechanistic investigations into how these disruptions lead to tumor cell death or reduced proliferation could be beneficial.
  • Clinical Translation: The findings provide strong preclinical evidence for MR as an adjunct therapy. The next logical step would be to explore MR in clinical trials for cancer patients, particularly in combination with existing therapies.

Summary updated

Abstract

Abstract Nutrition exerts profound effects on health and dietary interventions are commonly used to treat diseases of metabolic etiology. Although cancer has a substantial metabolic component, the principles that define whether nutrition may be used to influence tumour outcome are unclear. Nevertheless, it is established that targeting metabolic pathways with pharmacological agents or radiation can sometimes lead to controlled therapeutic outcomes. In contrast, whether specific dietary interventions could influence the metabolic pathways that are targeted in standard cancer therapies is not known. We now show that dietary restriction of methionine (MR), an essential amino acid, and the reduction of which has aging and obesogenic properties, influences cancer outcome through controlled and reproducible changes to one carbon metabolism. This pathway metabolizes methionine and further is the target of a host of cancer interventions involving chemotherapy and radiation. MR produced therapeutic responses in chemoresistant RAS-driven colorectal cancer patient derived xenografts and autochthonous KRAS G12D +/− ; TP53 −/− -driven soft tissue sarcomas resistant to radiation. Metabolomics revealed the therapeutic mechanisms to occur through tumor cell autonomous effects on the flux through one carbon metabolism that impacted redox and nucleotide metabolism, thus interacting with the antimetabolite or radiation intervention. Finally, in a controlled and tolerated feeding study in humans, MR resulted in similar effects on systemic metabolism as obtained in responsive mice. These findings provide evidence that a targeted dietary manipulation can affect specific tumor cell metabolism to mediate broad aspects of cancer outcome.
BibTeX
@misc{gao2019dietary,
  author = {Xia Gao and Sydney M. Sanderson and Ziwei Dai and Michael A. Reid and Daniel E. Cooper and Min Lu and John P. Richie and Amy Ciccarella and Ana Calcagnotto and Peter G. Mikhael and Samantha J. Mentch and Juan Liu and Gene P. Ables and David G. Kirsch and David S. Hsu and Sailendra N. Nichenametla and Jason W. Locasale},
  title = {{Dietary methionine restriction targets one carbon metabolism in humans and produces broad therapeutic responses in cancer}},
  year = {2019},
  doi = {10.1101/627364},
  howpublished = {bioRxiv},
}
Figure